Skip to main navigation Skip to search Skip to main content

Sacituzumab Govitecan: ein neues Antikörper-Wirkstoff-Konjugat für das metastasierte tripelnegative Mammakarzinom

Translated title of the contribution: Sacituzumab govitecan: a new antibody–drug conjugate for metastatic triple-negative breast cancer

M. Banys-Paluchowski*, Natalia Krawczyk

*Corresponding author for this work
Translated title of the contributionSacituzumab govitecan: a new antibody–drug conjugate for metastatic triple-negative breast cancer
Original languageGerman
JournalOnkologe
Volume27
Issue number3
Pages (from-to)287-290
Number of pages4
ISSN0947-8965
DOIs
Publication statusPublished - 03.2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Research Areas and Centers

  • Research Area: Luebeck Integrated Oncology Network (LION)
  • Centers: University Cancer Center Schleswig-Holstein (UCCSH)

Cite this